
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Human Cancer Biology |
Authors' Affiliations: 1 Department of Haematology, University College London; 2 Department of Haematology, Royal Free Hospital; and 3 Great Ormond Street Hospital, London, United Kingdom
Requests for reprints: Marc R. Mansour, Department of Haematology, University College London, 98 Chenies Mews, London WC1E 6HX, United Kingdom. E-mail: m.mansour{at}ucl.ac.uk.
Purpose: Activating Notch-1 mutations are frequent in T-cell acute lymphoblastic leukemia (T-ALL), occurring in >50% of patients. In murine models of T-ALL, Notch-1 activation can both directly initiate leukemia and cooperate secondarily to other primary events. Whether acquisition of Notch-1 mutations is an early initiating event or a secondary event in the pathogenesis of human T-ALL is unclear.
Experimental Design: We used denaturing high-performance liquid chromatography, sequencing, and fragment analysis to analyze Notch-1 mutational status and mutant level in 62 patients at presentation as well as 16 matched presentation-relapse samples.
Results: We detected Notch-1 mutations in 47 patients (76%). Seven of these were low-level mutations (quantified at
10%), despite high blast counts, suggesting that they were acquired as a secondary event in a subclone. Of 16 matched presentation-relapse samples studied, 7 were wild-type at both presentation and relapse. Five of nine mutant-positive patients at presentation relapsed with the same mutation(s) at the same high level. Four patients had evidence of a change in mutant at relapse. One lost a PEST mutation and became wild-type. Two others lost mutations at relapse but acquired different mutations, despite unchanged T-cell receptor rearrangements, suggesting that the latter event predated the acquisition of the Notch-1 mutation. One relapsed with a secondary T-cell leukemia and different Notch mutation.
Conclusions: These results suggest that Notch-1 mutations can sometimes be acquired as secondary events in leukemogenesis and must be used cautiously as solitary minimal residual disease markers.
This article has been cited by other articles:
![]() |
W. R. Gordon, M. Roy, D. Vardar-Ulu, M. Garfinkel, M. R. Mansour, J. C. Aster, and S. C. Blacklow Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL Blood, April 30, 2009; 113(18): 4381 - 4390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-C. Tien, A. Rajan, and H. J. Bellen A Notch updated J. Cell Biol., March 9, 2009; 184(5): 621 - 629. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Levy, J. A. Kahana, and R. Kumar AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines Blood, February 19, 2009; 113(8): 1723 - 1729. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |